FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025910660> ?p ?o ?g. }

• W2025910660 endingPage "783" @default.
• W2025910660 startingPage "781" @default.
• W2025910660 abstract "T the 20th century, men with minimally symptomatic benign prostatic hyperplasia (BPH) were generally advised to defer treatment. During most of this period, prostatectomy was the only accepted treatment, and, despite advances in surgical care, observation alone was considered preferable to surgery for men with few symptoms, provided no complications were present. In such cases, treatment deferral has always appeared reasonable, because mild “prostatism” is not bothersome and often seems a normal part of the aging process, progression is usually slow, symptoms often regress spontaneously, and surgical treatment entails the possibility of complications and the likelihood of retrograde ejaculation. However, effective nonoperative treatment for men with BPH has recently become available,3,4 and the “watchful waiting” dogma should now be reevaluated when substantial enlargement of the prostate is discovered. This reasoning is based on an emerging body of knowledge revealing that (a) BPH is a progressive condition in many men, (b) progression of BPH commonly leads to complications that are life-altering, to hospitalization, and to surgery, (c) identification of men at risk of BPH progression is now possible, and (d) well-tolerated medical therapy can help prevent BPH progression and reduce the incidence of acute urinary retention and the need for surgery. Thus, certain men— mainly those with prostate volumes exceeding 30 cm—have become compelling candidates for preventive medical treatment, even though their symptom scores may be low. BPH progression in middle-age men generally involves (a) an increasing prostate gland volume, as much as 2.4 cm/yr,5,6 (b) symptomatic deterioration (International Prostate Symptom Score) in 55%,7 (c) decreasing urinary flow, as much as 4.5%/yr,8 and, ultimately, (d) development of complications and the need for surgery in up to 34% of men.9,10 Such evidence of BPH progression has been found in community-based longitudinal and cross-sectional studies (eg, the Baltimore Longitudinal Study of Aging and the Olmsted County Study) and in the placebo-treated control patients of large randomized trials. The evidence for BPH progression has been qualitatively consistent in a wide variety of studies. The complications from BPH progression include bleeding, infection, stone formation, and acute urinary retention (AUR), the last usually necessitating surgical intervention. In the Olmsted County study, a 60-year-old man with moderate symptoms of BPH had a 10-year average risk for AUR of 13.7%, several times greater than his risk of hip fracture (4.9%), stroke (7.2%), or myocardial infarction (5.1%)11 (Fig. 1). In men with prostate volumes exceeding 30 cm, the risk of AUR is considerably greater than average (see below). Preventive measures are now widely used for hip fracture, stroke, and myocardial infarction. Although AUR is not life-threatening, it is a serious morbid event, usually accompanied by great discomfort, hospitalization, and surgery. Prevention would be desirable. L. S. Marks is a paid consultant to, speaker for, and/or investigator for GlaxoSmithKline, Merck & Company, BeckmanCoulter Inc., Sanofi-Synthelabo, Pfizer, Bayer, Lilly. From the Department of Urology, University of California, Los Angeles, Geffen School of Medicine; and Urological Sciences Research Foundation, Los Angeles, California Reprint requests: Leonard S. Marks, M.D., Urological Sciences Research Foundation, Culver Medical Plaza, 3831 Hughes Avenue, Suite 501, Culver City, CA 90232 Submitted: May 16, 2003, accepted (with revisions): July 14, 2003 EDITORIAL" @default.
• W2025910660 created "2016-06-24" @default.
• W2025910660 creator A5003945364 @default.
• W2025910660 date "2003-11-01" @default.
• W2025910660 modified "2023-09-24" @default.
• W2025910660 title "Treatment of men with minimally symptomatic benign prostatic hyperplasia—PRO: the argument in favor" @default.
• W2025910660 cites W1964370987 @default.
• W2025910660 cites W1986472546 @default.
• W2025910660 cites W2010616721 @default.
• W2025910660 cites W2011962188 @default.
• W2025910660 cites W2018009871 @default.
• W2025910660 cites W2051592657 @default.
• W2025910660 cites W2082709973 @default.
• W2025910660 cites W2089030366 @default.
• W2025910660 cites W2090957192 @default.
• W2025910660 cites W2096563779 @default.
• W2025910660 cites W2131822201 @default.
• W2025910660 cites W2400988469 @default.
• W2025910660 cites W2804551733 @default.
• W2025910660 doi "https://doi.org/10.1016/s0090-4295(03)00779-9" @default.
• W2025910660 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14624893" @default.
• W2025910660 hasPublicationYear "2003" @default.
• W2025910660 type Work @default.
• W2025910660 sameAs 2025910660 @default.
• W2025910660 citedByCount "7" @default.
• W2025910660 countsByYear W20259106602013 @default.
• W2025910660 crossrefType "journal-article" @default.
• W2025910660 hasAuthorship W2025910660A5003945364 @default.
• W2025910660 hasConcept C121608353 @default.
• W2025910660 hasConcept C126322002 @default.
• W2025910660 hasConcept C126894567 @default.
• W2025910660 hasConcept C2776235491 @default.
• W2025910660 hasConcept C2777562237 @default.
• W2025910660 hasConcept C29456083 @default.
• W2025910660 hasConcept C2994223898 @default.
• W2025910660 hasConcept C61434518 @default.
• W2025910660 hasConcept C71924100 @default.
• W2025910660 hasConcept C98184364 @default.
• W2025910660 hasConceptScore W2025910660C121608353 @default.
• W2025910660 hasConceptScore W2025910660C126322002 @default.
• W2025910660 hasConceptScore W2025910660C126894567 @default.
• W2025910660 hasConceptScore W2025910660C2776235491 @default.
• W2025910660 hasConceptScore W2025910660C2777562237 @default.
• W2025910660 hasConceptScore W2025910660C29456083 @default.
• W2025910660 hasConceptScore W2025910660C2994223898 @default.
• W2025910660 hasConceptScore W2025910660C61434518 @default.
• W2025910660 hasConceptScore W2025910660C71924100 @default.
• W2025910660 hasConceptScore W2025910660C98184364 @default.
• W2025910660 hasIssue "5" @default.
• W2025910660 hasLocation W20259106601 @default.
• W2025910660 hasLocation W20259106602 @default.
• W2025910660 hasOpenAccess W2025910660 @default.
• W2025910660 hasPrimaryLocation W20259106601 @default.
• W2025910660 hasRelatedWork W1981808053 @default.
• W2025910660 hasRelatedWork W2076364088 @default.
• W2025910660 hasRelatedWork W2126685696 @default.
• W2025910660 hasRelatedWork W2129303390 @default.
• W2025910660 hasRelatedWork W2379106945 @default.
• W2025910660 hasRelatedWork W2392413698 @default.
• W2025910660 hasRelatedWork W2414134228 @default.
• W2025910660 hasRelatedWork W2972454727 @default.
• W2025910660 hasRelatedWork W2979366738 @default.
• W2025910660 hasRelatedWork W4250202287 @default.
• W2025910660 hasVolume "62" @default.
• W2025910660 isParatext "false" @default.
• W2025910660 isRetracted "false" @default.
• W2025910660 magId "2025910660" @default.
• W2025910660 workType "article" @default.